dr. brufsky discusses pertuzumab in her2 breast cancer
Published 6 years ago • 85 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
1:41
dr. brufsky on implementing pertuzumab in her2 breast cancer
-
1:22
dr. brufsky on trastuzumab and eribulin for her2 metastatic breast cancer
-
1:01
dr. brufsky on trastuzumab biosimilars in breast cancer
-
2:39
adam brufsky, md, phd, describes the treatment landscape of her2 metastatic breast cancer
-
2:33
dr. brufsky discusses resistance to her2-targeted therapies
-
1:49
dr. brufsky on multiparametric genomic assays in breast cancer
-
1:06
dr. brufsky on challenges in breast cancer
-
2:00
adam brufsky, md, phd, discusses the issue of resistance to her2-targeted therapy
-
0:35
dr. brufsky discusses bevacizumab benefits in tnbc
-
1:16
dr. brufsky advises doctors on bevacizumab for breast cancer
-
1:13
dr. pegram discusses adjuvant pertuzumab in her2 breast cancer
-
1:53
dr. pegram on pertuzumab combination for her2-positive breast cancer
-
1:38
dr. brufsky on the results of a study of trastuzumab and eribulin for her2 mbc
-
0:30
dr. brufsky on adjuvant bisphosphonates for patients with breast cancer
-
1:05
dr. pegram on pertuzumab plus trastuzumab and chemotherapy in breast cancer
-
1:46
dr. brufsky discusses adjuvant bisphosphonates as a new standard of care
-
1:07
dr. brufsky on challenges facing biosimilars in breast cancer
-
2:12
dr adam brufsky discusses value coordinates of breast cancer care
-
1:51
dr. kolberg on cost-effectiveness of pertuzumab in her2-positive breast cancer